Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Relmada Therapeutics Inc is a biotechnology business based in the US. Relmada Therapeutics shares (RLMD) are listed on the NASDAQ and all prices are listed in US Dollars. Relmada Therapeutics employs 14 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$23.63|
|52-week range||$20.60 - $40.00|
|50-day moving average||$25.90|
|200-day moving average||$30.67|
|Wall St. target price||$72.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-5.24|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-9.71%|
|1 month (2021-09-17)||-14.26%|
|3 months (2021-07-16)||-24.19%|
|6 months (2021-04-16)||-31.88%|
|1 year (2020-10-16)||-32.21%|
|2 years (2019-10-16)||2.29%|
|3 years (2018-10-16)||2,048.18%|
|5 years (2016-10-14)||2,263.00%|
|Gross profit TTM||$0|
|Return on assets TTM||-44.31%|
|Return on equity TTM||-75.46%|
|Market capitalisation||$457.3 million|
TTM: trailing 12 months
There are currently 1.0 million Relmada Therapeutics shares held short by investors – that's known as Relmada Therapeutics's "short interest". This figure is 0.8% down from 1.0 million last month.
There are a few different ways that this level of interest in shorting Relmada Therapeutics shares can be evaluated.
Relmada Therapeutics's "short interest ratio" (SIR) is the quantity of Relmada Therapeutics shares currently shorted divided by the average quantity of Relmada Therapeutics shares traded daily (recently around 144495.45454545). Relmada Therapeutics's SIR currently stands at 7.04. In other words for every 100,000 Relmada Therapeutics shares traded daily on the market, roughly 7040 shares are currently held short.
However Relmada Therapeutics's short interest can also be evaluated against the total number of Relmada Therapeutics shares, or, against the total number of tradable Relmada Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Relmada Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Relmada Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0768% of the tradable shares (for every 100,000 tradable Relmada Therapeutics shares, roughly 77 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Relmada Therapeutics.
Find out more about how you can short Relmada Therapeutics stock.
We're not expecting Relmada Therapeutics to pay a dividend over the next 12 months.
Relmada Therapeutics's shares were split on a 1:4 basis on 29 September 2019. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Relmada Therapeutics shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Relmada Therapeutics shares which in turn could have impacted Relmada Therapeutics's share price.
Over the last 12 months, Relmada Therapeutics's shares have ranged in value from as little as $20.6 up to $40. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Relmada Therapeutics's is 0.2434. This would suggest that Relmada Therapeutics's shares are less volatile than average (for this exchange).
Relmada Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.